Slideshow

PSA screening: What do you tell primary care docs?

We asked several urologists about whether they advocate for PSA screening to primary care physicians in their area. 

slideshow image
Related Videos
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Prostate cancer screening: Expert weighs in after Biden's diagnosis
1 expert in this video
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
1 expert in this video
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Study results affirm effectiveness of evolving prostate cancer therapies
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
1 expert in this video
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
An Overview of the ARANOTE Trial
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
Related Content
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
May 20th 2025

Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer

Hannah Clarke
Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Study shows value of precision-based approaches in prostate cancer
May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke
The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr_Microbe - stock.adobe.come
May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke
Use of focal therapy was shown to prolong the duration of active surveillance.
© 2025 MJH Life Sciences

All rights reserved.